Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis

Authors :: K. Prajapati
Laura Airas
L. Mehta
K. Coutant
Marianna Manfrini
H. Koendgen
H.-P. Hartung
Bruno Brochet
Jerry S. Wolinsky
Ludwig Kappos
Robert T. Naismith
Source :: Journal of the Neurological Sciences. 405:31
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: medicine.medical_specialty
business.industry
medicine.medical_treatment
Primary Progressive Multiple Sclerosis
Neurology
Internal medicine
medicine
In patient
Disability progression
Ocrelizumab
Neurology (clinical)
business
Reduction (orthopedic surgery)
medicine.drug

Tools